Evolution of the Average Target: Genmab A/S

Data source: Genmab A/S(GMAB)
Evolution of the Average Target - Genmab A/S

Evolution of the Target Price: Genmab A/S

Data source: Genmab A/S(GMAB)
Evolution of the Target Price - Genmab A/S

Changes in Analyst Recommendations: Genmab A/S

Data source: Genmab A/S(GMAB)
3bd89c249409ee08fdb9c56209f28f.Xe-3OIaY2T-xE2BKDEgkRpgEjGMqW0DkgPQxEZOEj-U.KrXySPHJ6HX0dAt_ZgJidtpI4QVAExLR87BrVfu82NcksINW1q6gDvV3NQ~0411ad8569b3079f1866a90e7079b31c
14/10 UBS Raises Genmab Price Target to DKK 3,100 (2,700), Reiterates Buy FW
13/10 BNP Paribas raises its price target for Genmab to DKK 2,850 (2,600), reiterates outperform - BN FW
09/10 BofA 'Bullish' on Genmab's Upcoming Phase 3 Readouts; Buy Rating Maintained MT
09/10 Deutsche Bank raises price target for Genmab to 3,000 Danish kroner, reiterates buy FW
09/10 Deutsche Bank raises price target for Genmab to DKK 3,000 (2,750), reiterates buy FW
09/10 Barclays raises price target for Genmab to DKK 3,100 (2,900), reiterates overweight FW
07/10 Genmab: Beyond Darzalex Alphavalue
07/10 Deutsche Bank Research Raises Genmab PT, Keeps Buy Rating MT
07/10 Deutsche Bank reiterates buy on Genmab, raises price target to DKK 2,750 FW
07/10 DNB Carnegie raises price target for Genmab to DKK 2,850 (2,300), reiterates buy FW
06/10 Bank of America raises target price for Genmab to 2,850 Danish kroner (2,500), reiterates buy FW
06/10 Deutsche Bank raises price target for Genmab to DKK 2,750 (2,500), reiterates buy FW
06/10 Genmab in Good Health, Schneider Lacks Energy Zonebourse
06/10 SEB reiterates Buy on Genmab, raises price target to DKK 3,000 (Update) FW
06/10 SEB raises its price target for Genmab to DKK 3,000 (2,600), reiterates buy FW
06/10 Barclays: Genmab's Epkinly beats expectations FW
05/10 Jyske Bank downgrades Genmab to hold (buy), target price DKK2,350 - BN FW
05/10 Guggenheim Securities raises price target for Genmab's American depositary receipts to $54 (45), reiterates buy FW
05/10 Jefferies raises price target for Genmab to 2,900 Danish kroner (2,800), reiterates buy FW
05/10 Barclays sees stronger phase 3 case for Genmab's Rina-S FW
05/10 SEB raises price target for Genmab to DKK 2,775 (2,600), reiterates buy FW
23/09 Kempen raises target price for Genmab: 'petosemtamab could be the biggest share-price driver in a decade' FW
08/09 Barclays raises Genmab price target to 2,900 Danish kroner (2,500), reiterates overweight - BN FW
03/09 Handelsbanken Adds Xvivo and Vimian as Sector Favorites, Drops Danish Duo FW
01/09 Deutsche Bank raises price target for Genmab to 2,500 Danish kroner, reiterates buy FW

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+32.97%
+14.74%
+38.45%
+12.07%
+18.26%
+44.87%
+38.06%
+24.78%
+8.87%
Average +25.90%
Weighted average by Cap. +26.76%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
2,502.00DKK
Average target price
2,723.93DKK
Spread / Average Target
+8.87%
High Price Target
3,310.00DKK
Spread / Highest target
+32.29%
Low Price Target
2,050.00DKK
Spread / Lowest Target
-18.07%

Analyst Consensus Detail

Analyst consensus - Genmab A/S

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Genmab A/S
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Genmab A/S